Health Care·Pharmaceuticals·$2.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.81 | N/A | -4.71% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.81 | N/A | -4.71% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about the current market conditions. They highlighted the need for strategic adjustments moving forward.
Management acknowledged the challenges faced in the quarter.
They emphasized a focus on long-term strategies despite current performance.
The earnings report indicates that Organon & Co faced challenges, resulting in a slight miss on EPS. The stock reaction of a 15% decline reflects investor concerns about the company's performance and lack of guidance. The management's defensive tone suggests they are aware of the difficulties ahead and are focusing on long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
FIRSTENERGY CORP
Feb 13, 2023